Special clinical interests in prostate, urological, gynaecological and lung cancers, SABR/SBRT and palliative radiotherapy.
Dr Braden Higgs graduated from the University of Adelaide in 2000 before working as a junior doctor in London. He returned to South Australia for his specialist radiation oncology training at the Royal Adelaide Hospital. During 2010/11 he completed a fellowship at the Royal Brisbane and Women’s Hospital. Since then, he has held staff specialist positions at the Royal Adelaide and Queen Elizabeth Hospitals, where he is part of the uro-oncology, gynae-oncology, lung cancer and thyroid cancer multidisciplinary teams.
He was the Director of Training at the Royal Adelaide Hospital from 2015-2019 and continues to lecture Radiation Therapy students at the University of South Australia.
Braden is an executive member of the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG), which promotes best radiotherapeutic management for patients with genito-urinary cancers and coordinates national educational workshops. He is also a steering committee member of the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC). He has contributed to national (eviQ) treatment guidelines in prostate and gynaecological cancer.
He has a strong belief in the importance of clear and open communication with his patients and strives to deliver compassionate, high quality cancer care.
Braden is actively involved in clinical research and is the local principal investigator of several multi-centre national and international trials in prostate and kidney cancer. He has previously co-convened the annual scientific meetings of both the Australian and New Zealand College of Radiologists (RANZCR) and Australasian Brachytherapy Group (ABG).
- Executive member, FROGG
- Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand
- Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II) The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial
- TROG 15.03 phase II clinical trial of Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II
- Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method
- Comparison of effective I-131 half-life between thyroid hormone withdrawal and recombinant human thyroid- stimulating hormone for thyroid cancer: a retrospective study